OTHERS J ACTIVE-IMPLANTABLE DEVICES J ACTIVE-IMPLANTABLE DEVICES J ACTIVE-IMPLANTABLE DEVICES J01 ACTIVE-IMPLANTABLE CARDIAC DEVICES J ACTIVE-IMPLANTABLE DEVICES J0101 IMPLANTABLE PACEMAKERS J ACTIVE-IMPLANTABLE [...] ACCESSORIES J ACTIVE-IMPLANTABLE DEVICES J010199 PACEMAKERS - OTHERS J ACTIVE-IMPLANTABLE DEVICES J0102 ACTIVE-IMPLANTABLE CARDIAC DEVICES, DIAGNOSTIC J ACTIVE-IMPLANTABLE DEVICES J010201 ACTIVE-IMPLANTABLE [...] CONSUMABLES J ACTIVE-IMPLANTABLE DEVICES J0299 NEUROSTIMULATORS - OTHERS J ACTIVE-IMPLANTABLE DEVICES J03 AUDITORY ACTIVE-IMPLANTABLE DEVICES J ACTIVE-IMPLANTABLE DEVICES J0301 AUDITORY ACTIVE-IMPLANTABLE

Referenced at:

• Clinical investigations with medical devices

Recall due to foreign impurities

The product called "Mysem Life" is marketed as herbal mixture paste or Turkish honey mixture for men and women. However, it is to be classified as an illegal medicinal product.

The product called "Maximum Power" is marketed as herbal product or Turkish honey mixture. However, it is to be classified as an illegal medicinal product.

The product called "Shivanya Beauty Cream" is marketed as a supposed cosmetic product for skin whitening. However, it is to be classified as an illegal medicinal product.

Up-to-date information from the 18.07-21.07.2022 meeting on new approvals, extensions of indication, newly published EPARs and recently started procedures.

Diese Gebührenverordnung findet Anwendung auf alle Anbringen, die ab dem 15.08.2022 beim BASG eingegangen sind.

Referenced at:

• Fees

Recall due to increased allergen activity

EMA "core number" is displayed, e.g. EMEA/H/C/xxxxxx Active ingredients: Displays the active ingredient(s). If a medicinal product has several active substances, these are separated by the separator "I" [...] possible. Delivery status: Selection via drop-down menu. Multiple selection is possible. Active ingredient: Enter the active ingredient. The wildcard search with * or % is also possible here. Drug category: Selection

Up-to-date information from the 20.06-23.06.2022 meeting on new approvals, extensions of indication, newly published EPARs and recently started procedures.